Stock Detail
NEUROCRINE BIOSCIENCES INC
NBIX @ Yahoo Finance | NBIX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.51 | $6.78 | $-0.20 | -2.98% | 0.00 | $6.71 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.64 | $6.49 | 180,734 | 359.72M | 314,256.67 | 9.46 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 6.88 | 6.69 | 6.59 | 6.40 | 6.30 |
Stock Profile
Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Its product candidates address various pharmaceutical markets, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, and other neurological and endocrine related diseases and disorders. Neurocrine has 17 programs in various stages of research and development. Its lead clinical development program, indiplon, for the treatment of insomnia, partnered with Pfizer, Inc., is in Phase III clinical development. The company completed three Phase I single and multiple dose trials with Gonadotropin-releasing Hormone, GnRH, for the treatment of women's health disorders. It also has two Altered Peptide Ligand products in Phase II clinical development, NBI-5788 for multiple sclerosis and NBI-6024 for Type I Diabetes. Neurocrine initiated a Phase I clinical trial with its proprietary compound, urocortin 2 for treating mild to moderate congestive heart disease. The company's CRF program, partnered with GlaxoSmithKline, is developing multiple compounds that are in various stages of research and preclinical development. It also has strategic alliances with Almirall Prodesfarma, S.A.; Wyeth Holdings Corporation; and Eli Lilly and Company. The company was incorporated in 1992 and is headquartered in San Diego, California.